vertex pharmaceuticals news - Search News

Hosted on MSN · 5h

Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock,

MarketWatch · 1d

Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals Inc (VRTX) Stock: Analyzing Its Quiet Power

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 and touched a low of $401.

Zacks.com on MSN · 1d

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

MarketWatch · 2d

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

This was the stock's second consecutive day of gains.

6h

Shareholder Rights Advocates at Levi & Korsinsky Investigate Vertex Pharmaceuticals Incorporated (VRTX) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

4don MSN

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

3d

Vertex wins approval for new once-daily CF drug

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

2d

Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $430.00 Price Target at Scotiabank

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

1d

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...

Zacks.com on MSN1d

Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor ...

3d

Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...

Vertex Wins FDA Approval for New Cystic Fibrosis Option but Stock Still Down

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results